Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Cyclin D1 Overexpression Predicts Poor Disease-Specific Survival in Human Papillomavirus-Independent Vulvar Squamous Cell Carcinoma

  • Carreras-Dieguez, Núria|||0000-0002-4809-8102
  • Ordi, Oriol
  • Peñuelas, Núria|||0000-0001-6443-9790
  • del Pino, Marta|||0000-0003-2178-2403
  • Diez-Ahijado, Laia
  • Darecka, Katarzyna
  • Marimón, Lorena|||0000-0002-2943-3550
  • Vega, Naiara
  • Torne, Aureli|||0000-0003-4700-9507
  • Saco, Adela
  • Albero Gallego, Robert|||0000-0001-5527-0997
  • Gaba, Lydia
  • Rakislova, Natalia|||0000-0001-5030-3526
The amplification of CCND1 is associated with the development and progression of various cancers. In a recent study, we showed that almost all adverse outcomes in vulvar squamous cell carcinomas (VSCC) occurred in patients with human papillomavirus (HPV)-independent, TP53-mutated tumors harboring CCND1 gains. In this study, we analyzed the association between CCND1 gain, cyclin D1 immunohistochemistry (IHC), and disease-specific survival (DSS) in a series of patients with HPV-independent VSCC. All patients who underwent primary surgery for VSCC at the Hospital Clínic of Barcelona, Spain, from 1975 to 2023 were recruited ("overall" cohort, n = 139). IHC for p53 and cyclin D1 was performed in all cases. In a subset of patients, we performed DNA sequencing to evaluate CCND1 copy number variations ("sequencing" cohort, n = 54). Cyclin D1 IHC overexpression (≥50% of tumor cells) had 94% sensitivity and 67% specificity as a surrogate marker of CCND1 gain. In the "sequencing" cohort, only CCND1 gains were significantly associated with impaired DSS in the multivariate analysis (hazard ratio [HR], 4.15; 95% CI, 1.08-5.40; P =.032), whereas stage or mutant TP53 status did not reach statistical significance. In the "overall" cohort, advanced stage (HR, 2.41; 95% CI, 1.08-5.39; P =.032) and cyclin D1 IHC overexpression (HR, 4.89; 95% CI, 1.77-18.5; P =.001) were associated with worse DSS in the multivariate analysis, whereas abnormal p53 IHC was not (HR, 5.06; 95% CI, 0.68-647; P =.138). In conclusion, cyclin D1 overexpression is an acceptable surrogate for CCND1 gain and has a much stronger adverse prognostic impact than altered p53 IHC in patients with HPV-independent VSCC.